Frivolt K, et al. - The impact of anti-tumor necrosis factor (TNF) therapy with infliximab (IFX) on serum adipokine levels in pediatric Crohn disease (CD) was investigated. For the purpose of this study, the researchers assessed serum concentrations of resistin (ng/mL), leptin (ng/mL), and total adiponectin (μg/mL) by enzyme-linked immunosorbent assays (ELISA) in eighteen pediatric CD patients (mean age 15.0 ± 1.5 years) before first, second, and fourth IFX infusion (weeks 0, 2, and 14) and compared with baseline values from sex- and BMI-matched healthy controls (HC, mean age 13.4 ± 1.6 years). It was observed in the findings that TNF blockade was correlated with changes in circulating adipokines. Results of this study suggested that the marked early increase of the potent anti-inflammatory adiponectin could contribute to the rapid response to IFX in CD.